tetano
Editor, Senior Moderator
J Infect Dis. 2020 May 2. pii: jiaa229. doi: 10.1093/infdis/jiaa229. [Epub ahead of print]
Longitudinal Change of SARS-Cov2 Antibodies in Patients with COVID-19.
Zhang G[SUP]1[/SUP], Nie S[SUP]1[/SUP], Zhang Z[SUP]1[/SUP], Zhang Z[SUP]1[/SUP].
Author information
Abstract
BACKGROUND:
A novel coronavirus, SARS-CoV-2, has recently emerged and caused the rapid spread of COVID-19 worldwide.
METHODS:
We did a retrospective study and included COVID-19 patients admitted to Renmin Hospital of Wuhan University between February 1 and February 29, 2020. Antibody assay was conducted to detect COVID-19 envelope protein E and nucleocapsid protein N antigen.
RESULTS:
112 patients were recruited with symptoms of fever, cough, fatigue, myalgia, and diarrhoea. All patients underwent antibody tests. Fifty-eight (51.79%) were positive for both IgM and IgG, 7 (6.25%) were negative for both antibodies, 1 (0.89%) was positive for only IgM, and 46 (41.07%) were positive for only IgG. IgM antibody appeared within a week post disease onset, and lasted for one month and gradually decreased, while IgG antibody was produced 10 days after infection, and lasted for a longer time. However, no significant difference in level of IgM and IgG antibody between positive and negative patients of nucleic acid test after treatment was found.
CONCLUSIONS:
Our results indicate that serological tests could be powerful approach for the early diagnosis of COVID-19.
? The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
KEYWORDS:
COVID-19; SARS-CoV-2; antibody; humoral immunity; serological test
PMID:32358956DOI:10.1093/infdis/jiaa229
Longitudinal Change of SARS-Cov2 Antibodies in Patients with COVID-19.
Zhang G[SUP]1[/SUP], Nie S[SUP]1[/SUP], Zhang Z[SUP]1[/SUP], Zhang Z[SUP]1[/SUP].
Author information
Abstract
BACKGROUND:
A novel coronavirus, SARS-CoV-2, has recently emerged and caused the rapid spread of COVID-19 worldwide.
METHODS:
We did a retrospective study and included COVID-19 patients admitted to Renmin Hospital of Wuhan University between February 1 and February 29, 2020. Antibody assay was conducted to detect COVID-19 envelope protein E and nucleocapsid protein N antigen.
RESULTS:
112 patients were recruited with symptoms of fever, cough, fatigue, myalgia, and diarrhoea. All patients underwent antibody tests. Fifty-eight (51.79%) were positive for both IgM and IgG, 7 (6.25%) were negative for both antibodies, 1 (0.89%) was positive for only IgM, and 46 (41.07%) were positive for only IgG. IgM antibody appeared within a week post disease onset, and lasted for one month and gradually decreased, while IgG antibody was produced 10 days after infection, and lasted for a longer time. However, no significant difference in level of IgM and IgG antibody between positive and negative patients of nucleic acid test after treatment was found.
CONCLUSIONS:
Our results indicate that serological tests could be powerful approach for the early diagnosis of COVID-19.
? The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
KEYWORDS:
COVID-19; SARS-CoV-2; antibody; humoral immunity; serological test
PMID:32358956DOI:10.1093/infdis/jiaa229